Pipeline

Developing Cell and Tissue-Based Therapies for a Range of Aesthetic & Medical Conditions

Bimini is commercializing and investigating autologous and allogenic products & therapies that are ready-to-use at the point-of-care and eliminate the need for matching patients with donors.

Bimini’s product portfolio has already been successfully used in clinical settings in hundreds of thousands of patients worldwide and has trials for androgenic alopecia and osteoarthritis of the knee. Bimini is in the early stages of unlocking the full potential of its product portfolio and adipose derived stem cell technology both in autologous and allogeneic form.

Medical Devices

PRODUCT/BRAND MARKET RESEARCH DEVELOPMENT CLEARANCE/APPROVAL
PUREGRAFT 50/250/850 BAGS US
CE MARK
JAPAN
PUREGRAFT MICROFAT US
CE MARK
JAPAN
HEALEON HD PRP US
CE MARK
JAPAN
HEALEON DUET US
CE MARK
JAPAN
DERMAPOSE US
CE MARK
JAPAN

Biologics

PRODUCT/BRAND MARKET RESEARCH DEVELOPMENT PHASE I/II PHASE III APPROVAL
KERASTEM US
CE MARK
JAPAN
KERASTEM ALLOGENIC US
CE MARK
JAPAN
CONVALESCENT PLASMA US
CE MARK
JAPAN